Integer Holdings Co. (NASDAQ:ITGR) was down 1.3% on Thursday . The stock traded as low as $22.83 and last traded at $23.05, with a volume of 355,212 shares changing hands. The stock had previously closed at $23.36.

Several equities research analysts recently weighed in on ITGR shares. TheStreet downgraded shares of Integer Holdings from a “hold” rating to a “sell” rating in a research report on Friday, July 1st. Zacks Investment Research raised shares of Integer Holdings from a “sell” rating to a “hold” rating in a research report on Thursday, May 19th. Finally, Sterne Agee CRT reissued a “buy” rating on shares of Integer Holdings in a research report on Monday, May 16th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the stock. Integer Holdings presently has an average rating of “Hold” and a consensus price target of $57.00.

The company’s market cap is $708.42 million. The stock has a 50 day moving average of $0.00 and a 200 day moving average of $0.00.

Integer Holdings (NASDAQ:ITGR) last released its quarterly earnings data on Thursday, July 28th. The company reported $0.56 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.70 by $0.14. The business had revenue of $348.38 million for the quarter, compared to the consensus estimate of $356.72 million. Integer Holdings’s revenue for the quarter was up 99.2% compared to the same quarter last year. During the same period last year, the business posted $0.73 earnings per share. On average, equities analysts expect that Integer Holdings Co. will post $2.64 EPS for the current fiscal year.

Greatbatch, Inc is a developer and manufacturer of medical devices and components. The Company operates through two segments: Greatbatch Medical and QiG Group (QiG). Greatbatch Medical designs and manufactures products where the Company either owns the intellectual property or has unique manufacturing and assembly expertise.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.